Enhancing bispecific antibody therapies with healthy donor T cells

Research unit

INNOSUISSE

Project number

100.763 IP-LS

Project title

Enhancing bispecific antibody therapies with healthy donor T cells

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Human medicine
Abstract (English)	Bispecific antibodies (biAbs) rely on autologous T cells which, in cancer patients, are often insufficient. Encelta has developed Allogeneic-Engineered-Decoupled (AED) T cells from healthy donors that can be used safely (no GvHD) and effectively against tumor cells when activated with a biAb.